PBMC vaccine is under clinical development by SQZ Biotechnologies and currently in Phase II for Vaginal Cancer. According to GlobalData, Phase II drugs for Vaginal Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PBMC vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PBMC vaccine overview
Cell therapy is under development for the treatment of solid tumor, human papillomavirus (HPV) associated cancers including cervical, head and neck cancers, anal cancer, rectal, penile cancer, vulval and vaginal cancer. The therapy consists of engineered B- cells which carry tumor-associated proteins or antigen. It is administered through intravenous route. It is developed based on CellSqueeze technology platform. The drug candidate is a new molecular entity.
It was also under development for solid tumors.
SQZ Biotechnologies overview
SQZ Biotechnologies (SQZ) is a pharmaceutical company. It develops cell-based therapies that harness the body’s natural immune system against cancer. The company utilizes CellSqueeze, a technology platform for engineering various cell functions as antigen presenting cells (APCs) for immune modulation to impact oncology and autoimmune disease applications. SQZ’s APC approach enables delivery of cancer-specific antigens to the cytosol of the APC which generates polyclonal T cell responses. The company collaborates with other academic institutions, pharmaceutical and biotechnology companies focusing on developing new cell therapies and approaches for that transform patient lives. It operates in Hong Kong and the US. SQZ is headquartered in Watertown, Massachusetts, the US.
For a complete picture of PBMC vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Pbmc Vaccine in Vaginal Cancer
Premium Insights
The gold standard of business intelligence.
